Severe Acute MalnutritionNCT05614505
Efficacy and Acceptability of RUTFs in Indonesia
A study testing Ready to use therapeutic foods in people with Severe Acute Malnutrition, run by Institut de Recherche pour le Developpement at 1 site in Indonesia.
Trial summary
Severe wasting or Severe Acute Malnutrition (SAM) continues to be a major public health problem in Indonesia, affecting more than 2 million children under 5 years old. A new approach to treat SAM is called Community-based management of acute malnutrition (CMAM), which has been designed to maximize the coverage and… Read more about this study
- Who is it for?
- Ages 6 to 59 months
- Conditions the study is for
- Severe Acute Malnutrition
- What is being tested?
- Ready to use therapeutic foods
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 300 participants
- Where
- 1 siteIndonesia
- Study dates
- 15 Jul 2021to 25 Jan 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 59 months
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Children with uncomplicated SAM (WHZ < -3 and/or MUAC <115 mm) qualified for outpatient treatment, or nutritional edema regardless of anthropometry
- Aged 6-59 months old upon enrolment
- Pass appetite test
- Never received in- and outpatient treatment on SAM (including not having consumed RUTF, F75, F100 or special medical specialty food1 in the last two months
- Willing to participate in the study (parent signed the informed consent)
Who cannot join
- Body weight < 4.0 kg;
- Uncontrolled or untreatable systemic opportunistic infection, such as active TB, HIV;
- Obvious dysmorphic features, general mental health problems (e.g., Down syndrome, etc.), other conditions interfering with normal growth;
- Participating in another clinical trial;
- Any congenital disorder that interferes with normal nutrient intake; chronic conditions including but not exclusively disorders of heart, kidney or liver (children to be screened by a physician);
- SAM with complications requiring hospital treatment (including edema +3);
Show all 9Show fewer
- Severe anemia (Hb<7g/dL);
- Is a twin or multiple;
- Allergy to milk, nuts, legumes and/or antibiotics (Amoxicillin and Ampicillin)
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Efficacy and Acceptability of Ready-to-use Therapeutic Foods (RUTFs) in Indonesia
Severe wasting or Severe Acute Malnutrition (SAM) continues to be a major public health problem in Indonesia, affecting more than 2 million children under 5 years old. A new approach to treat SAM is called Community-based management of acute malnutrition (CMAM), which has been designed to maximize the coverage and successful treatment of children with SAM, by providing Ready to Use Therapeutic Food (RUTF) through out-patient treatment. Since 2019, UNICEF has been working intensively to facilitate the local production of RUTF. This present study aims to assess the acceptability and efficacy of three locally produced RUTFs compared to the standard peanut based RUTF.
The study will be implemented in Bogor district. A total of 300 children with uncomplicated SAM, aged 6-59 months old, meeting the inclusion criteria will be included in the study. This study is designed as a randomized controlled trial. The children will be allocated to one of the five intervention (1 control, 4 experimental) arms. Each child will receive one type of RUTF product for eight consecutive weeks. The ration given to a child will be based on the need for an intake of ~ 170 kcal/kg BW/day. Data will be collected at baseline, at weekly intervals and at exit. The primary outcome of interest for the efficacy study is the relative weight gain of children consuming each of the local RUTFs compared with those consuming the standard RUTF. The primary outcome of the acceptability of the RUTFs will be the amount of product consumed during the eight-week efficacy trial.
Differences in weight and height gain will be analyzed using ANCOVA, controlling for age, gender, food intake, and morbidity. Repeated measurement statistics will be used to analyze differences in growth patterns over the eight-week intervention.
Read the detailed description
OBJECTIVES This study aims to assess the acceptability and efficacy to increase weight and mid upper arm circumference of children aged 6-59 months with severe acute malnutrition (SAM), of three locally produced RUTFs compared to the standard peanut based RUTF. The study will be implemented in Bogor district.
METHODOLOGY Subjects inclusion criteria are reported elsewhere.
Sample Size Calculation If the Indonesian RUTFs fulfil the WHO requirement of an average increase of 4 g/kg BW/day, a sample size of 60 children per group would allow detecting a 20% difference between control and intervention products, assuming a SD of 1.6 g/kg BW, a study design effect of 1.0, a significance of 0.05, a power of 0.80. If children fail to reach this 4 g/kg BW target and only gain 2 g/kg BW/day, the sample size would still allow detection of a 30% difference between the control product and the local product. Since it will be a five-armed intervention, a total of 300 SAM children will be recruited in Bogor district.
Anthropometric and Hemoglobin Measurements Training The training on anthropometric measurements will include repeated practice and comparison of intra- and inter-observer variation to ensure that the field team will have excellent skills in conducting the anthropometric measurements.
Hemoglobin concentration will be measured using Hemocue 201+ device by (or under direct supervision of) a medical doctor, trained in the use of the equipment.
Study Design This study is designed as an individually randomised controlled trial. Parents will be informed of the purpose, risks and benefits of the study and asked to sign the informed consent prior to inclusion of their child in the study.
Each child will be randomly allocated to one of the five intervention arms.
Acceptability Study The primary outcome of the acceptability of the RUTFs will be the amount of product consumed during the 8-week efficacy trial (long-term acceptability). An average consumption of at least 50% of the offered product during the 8-week efficacy trial will be considered acceptable.
The secondary outcome of the acceptability study will be the consumption velocity of the RUTFs during the appetite test (short-term acceptability; see below).
Efficacy Study The primary outcome of interest for the efficacy study is the relative weight gain of children consuming each of the local RUTFs compared with those consuming the standard RUTF. A difference of 20% in weight gain will be considered as physiologically significant.
Randomization Prior to the appetite test, selected children with uncomplicated SAM will be randomized to one of the five intervention arms. The randomization list is made prior to recruitment by a member of the research team not present in the field (FTW). Children randomized to one arm will receive the standard RUTF product, and the other four arms will each receive one of four local RUTFs.
Appetite Test The day after the screening, selected children will need to pass an appetite test prior to enrolment in the intervention.
Design Each child will receive one type of RUTF products for eight consecutive weeks. Data will be collected at baseline, at weekly intervals and at exit. Children who completely refuse to eat the RUTF they have been allocated to for more than 4 days/week, for 2 consecutive weeks, or children who lose or do not gain weight during 2 consecutive weekly visits, and/or develop allergic reaction and clinical symptoms during the course of the study will be dropped from the study and will be referred to the Puskesmas for treatment.
A weekly supply of RUTF will be supplied during each of the weekly check-up visits.
Baseline data General information on socio-economic status of the family, ethnicity, educational level of both parents, household food security, IYCF including 24 h food recall, use of micronutrient supplements (vitamin A, iron, syrup) and supplementary foods (PMT/Local PMT), morbidity history and current morbidity, duration of pregnancy, birth weight, immunization status, deworming, sex and age of the child, will be collected at baseline, in addition to height/length, weight, MUAC and hemoglobin concentration. All data will be recorded using a digital questionnaire on tablet computers.
Monitoring The daily amount of RUTF intake of each child will be recorded by the mother/caregiver in a monitoring book provided by the study team. The field team will visit each child on a weekly basis to monitor the feeding and intake recording by the mother/caregiver, as well as any intra-household sharing of the RUTF.
In addition to the weekly home visits, the PL will maintain regular daily communication with the mothers/caregivers through text messages.
Data Analysis The baseline, monitoring, and endline data will be entered in a digital questionnaire by the field workers. The researcher will extract data from digital questionnaire into SPSS format. Data analyses will be done using SPSS.
- Conditions
- Severe Acute Malnutrition
- Being tested
- Ready to use therapeutic foods
- Keywords
- Ready to use therapeutic food (RUTF), acceptability, local, children, rehabilitation
- Medical subject headings
- Severe Acute Malnutrition
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ready to use therapeutic foodsDietary supplement
locally produced therapeutic foods
| Study group | Role | What they receive |
|---|---|---|
| RUTF standard | Active comparator | PlumpyNut Receives: Dietary Supplement: Ready to use therapeutic foods |
| RUTF local_1 | Experimental | Soybean RUTF Receives: Dietary Supplement: Ready to use therapeutic foods |
| RUTF local_2 | Experimental | Mungbean-thick RUTF Receives: Dietary Supplement: Ready to use therapeutic foods |
| RUTF local_3 | Experimental | Mungbean-thin RUTF Receives: Dietary Supplement: Ready to use therapeutic foods |
| RUTF local_4 | Experimental | Wafer RUTF Receives: Dietary Supplement: Ready to use therapeutic foods |
What is being measured
The primary outcome is the main question the study is designed to answer.
short-term acceptability
Passing the appetite test
Measured: consumption of at least 50% of RUTF provided in a 30 minute period
long-term acceptability
drop-out during the intervention
Measured: Number of children not finishing the 8 week intervention
weight gain over the 8 week intervention
weight gain (in g) over 8 week intervention
Measured: weight gain expressed as weight gain (g)/kg body weight per day over the 8 week intervention
Secondary outcomes (5)
recovery rate
percentage of children having WHZ>-2 and/or MUAC >125 mm
Measured: from baseline to end of the 8 week intervention
increase in height for age Z scores (HAZ)
changes in length growth among the intervention arms
Measured: from baseline to the end of the 8 week intervention
length of stay in the treatment
Average number of day in treatment to reach recovery or drop-out
Measured: 8 week intervention or shorter
Morbidity during the intervention
number of sick days based on the weekly recall data
Measured: from baseline to 8 week intervention
Perception
Acceptability of the product by caregivers
Measured: based on the interview with the caregiver after the 8 week intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Nov 2022
- Study start15 Jul 2021
- Primary completion15 Dec 2021
- Study completion25 Jan 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Severe Acute MalnutritionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- randomized controlled trial
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 300 participants (actual)
Sponsor and investigators
- Lead sponsor
- Institut de Recherche pour le Developpement
- Sponsor type
- Other government
- Collaborators
- Savica, UNICEF
- Responsible party
- Principal investigator, Frank Wieringa, Institut de Recherche pour le Developpement
- Investigators
- Frank Wieringa, MD PhD, Principal investigator, Institute de Recherche pour le Développement
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05614505
- Sponsor's protocol ID
- RUTF_2021_Impact
- Status last verified
- Nov 2022
- First submitted
- 22 Sep 2021
- Last updated
- 14 Nov 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Yes, IP data will be available upon request
Study at a glance
From the registry record, last updated by the sponsor on 14 Nov 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy and Acceptability of Ready-to-use Therapeutic Foods (RUTFs) in Indonesia
- ClinicalTrials.gov ID
- NCT05614505
- Acronym / sponsor ID
- RUTF_2021_Impact
- Conditions
- Severe Acute Malnutrition
- Keywords
- Ready to use therapeutic food (RUTF), acceptability, local, children, rehabilitation
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 300 participants (actual)
- Lead sponsor
- Institut de Recherche pour le DeveloppementOther government
- Collaborators
- Savica, UNICEF
- Study start
- 15 Jul 2021 (actual)
- Primary completion
- 15 Dec 2021 (actual)
- Study completion
- 25 Jan 2022 (actual)
- First posted
- 14 Nov 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Severe wasting or Severe Acute Malnutrition (SAM) continues to be a major public health problem in Indonesia, affecting more than 2 million children under 5 years old. A new approach to treat SAM is called Community-based management of acute malnutrition (CMAM), which has been designed to maximize the coverage and successful treatment of children with SAM, by providing Ready to Use Therapeutic Food (RUTF) through out-patient treatment. Since 2019, UNICEF has been working intensively to facilitate the local production of RUTF. This present study aims to assess the acceptability and efficacy of three locally produced RUTFs compared to the standard peanut based RUTF.
The study will be implemented in Bogor district. A total of 300 children with uncomplicated SAM, aged 6-59 months old, meeting the inclusion criteria will be included in the study. This study is designed as a randomized controlled trial. The children will be allocated to one of the five intervention (1 control, 4 experimental) arms. Each child will receive one type of RUTF product for eight consecutive weeks. The ration given to a child will be based on the need for an intake of ~ 170 kcal/kg BW/day. Data will be collected at baseline, at weekly intervals and at exit. The primary outcome of interest for the efficacy study is the relative weight gain of children consuming each of the local RUTFs compared with those consuming the standard RUTF. The primary outcome of the acceptability of the RUTFs will be the amount of product consumed during the eight-week efficacy trial.
Differences in weight and height gain will be analyzed using ANCOVA, controlling for age, gender, food intake, and morbidity. Repeated measurement statistics will be used to analyze differences in growth patterns over the eight-week intervention.
Detailed description
OBJECTIVES This study aims to assess the acceptability and efficacy to increase weight and mid upper arm circumference of children aged 6-59 months with severe acute malnutrition (SAM), of three locally produced RUTFs compared to the standard peanut based RUTF. The study will be implemented in Bogor district.
METHODOLOGY Subjects inclusion criteria are reported elsewhere.
Sample Size Calculation If the Indonesian RUTFs fulfil the WHO requirement of an average increase of 4 g/kg BW/day, a sample size of 60 children per group would allow detecting a 20% difference between control and intervention products, assuming a SD of 1.6 g/kg BW, a study design effect of 1.0, a significance of 0.05, a power of 0.80. If children fail to reach this 4 g/kg BW target and only gain 2 g/kg BW/day, the sample size would still allow detection of a 30% difference between the control product and the local product. Since it will be a five-armed intervention, a total of 300 SAM children will be recruited in Bogor district.
Anthropometric and Hemoglobin Measurements Training The training on anthropometric measurements will include repeated practice and comparison of intra- and inter-observer variation to ensure that the field team will have excellent skills in conducting the anthropometric measurements.
Hemoglobin concentration will be measured using Hemocue 201+ device by (or under direct supervision of) a medical doctor, trained in the use of the equipment.
Study Design This study is designed as an individually randomised controlled trial. Parents will be informed of the purpose, risks and benefits of the study and asked to sign the informed consent prior to inclusion of their child in the study.
Each child will be randomly allocated to one of the five intervention arms.
Acceptability Study The primary outcome of the acceptability of the RUTFs will be the amount of product consumed during the 8-week efficacy trial (long-term acceptability). An average consumption of at least 50% of the offered product during the 8-week efficacy trial will be considered acceptable.
The secondary outcome of the acceptability study will be the consumption velocity of the RUTFs during the appetite test (short-term acceptability; see below).
Efficacy Study The primary outcome of interest for the efficacy study is the relative weight gain of children consuming each of the local RUTFs compared with those consuming the standard RUTF. A difference of 20% in weight gain will be considered as physiologically significant.
Randomization Prior to the appetite test, selected children with uncomplicated SAM will be randomized to one of the five intervention arms. The randomization list is made prior to recruitment by a member of the research team not present in the field (FTW). Children randomized to one arm will receive the standard RUTF product, and the other four arms will each receive one of four local RUTFs.
Appetite Test The day after the screening, selected children will need to pass an appetite test prior to enrolment in the intervention.
Design Each child will receive one type of RUTF products for eight consecutive weeks. Data will be collected at baseline, at weekly intervals and at exit. Children who completely refuse to eat the RUTF they have been allocated to for more than 4 days/week, for 2 consecutive weeks, or children who lose or do not gain weight during 2 consecutive weekly visits, and/or develop allergic reaction and clinical symptoms during the course of the study will be dropped from the study and will be referred to the Puskesmas for treatment.
A weekly supply of RUTF will be supplied during each of the weekly check-up visits.
Baseline data General information on socio-economic status of the family, ethnicity, educational level of both parents, household food security, IYCF including 24 h food recall, use of micronutrient supplements (vitamin A, iron, syrup) and supplementary foods (PMT/Local PMT), morbidity history and current morbidity, duration of pregnancy, birth weight, immunization status, deworming, sex and age of the child, will be collected at baseline, in addition to height/length, weight, MUAC and hemoglobin concentration. All data will be recorded using a digital questionnaire on tablet computers.
Monitoring The daily amount of RUTF intake of each child will be recorded by the mother/caregiver in a monitoring book provided by the study team. The field team will visit each child on a weekly basis to monitor the feeding and intake recording by the mother/caregiver, as well as any intra-household sharing of the RUTF.
In addition to the weekly home visits, the PL will maintain regular daily communication with the mothers/caregivers through text messages.
Data Analysis The baseline, monitoring, and endline data will be entered in a digital questionnaire by the field workers. The researcher will extract data from digital questionnaire into SPSS format. Data analyses will be done using SPSS.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, care provider)
- Number of arms
- 5
- Model description
- randomized controlled trial
| Arm | Type | Receives |
|---|---|---|
| RUTF standard | Active comparator | Dietary Supplement: Ready to use therapeutic foodsPlumpyNut |
| RUTF local_1 | Experimental | Dietary Supplement: Ready to use therapeutic foodsSoybean RUTF |
| RUTF local_2 | Experimental | Dietary Supplement: Ready to use therapeutic foodsMungbean-thick RUTF |
| RUTF local_3 | Experimental | Dietary Supplement: Ready to use therapeutic foodsMungbean-thin RUTF |
| RUTF local_4 | Experimental | Dietary Supplement: Ready to use therapeutic foodsWafer RUTF |
Who may qualify
- Ages
- 6 to 59 months
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (5 listed)
- Children with uncomplicated SAM (WHZ < -3 and/or MUAC <115 mm) qualified for outpatient treatment, or nutritional edema regardless of anthropometry
- Aged 6-59 months old upon enrolment
- Pass appetite test
- Never received in- and outpatient treatment on SAM (including not having consumed RUTF, F75, F100 or special medical specialty food1 in the last two months
- Willing to participate in the study (parent signed the informed consent)
Key exclusion criteria (9 listed)
- Body weight < 4.0 kg;
- Uncontrolled or untreatable systemic opportunistic infection, such as active TB, HIV;
- Obvious dysmorphic features, general mental health problems (e.g., Down syndrome, etc.), other conditions interfering with normal growth;
- Participating in another clinical trial;
- Any congenital disorder that interferes with normal nutrient intake; chronic conditions including but not exclusively disorders of heart, kidney or liver (children to be screened by a physician);
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ready to use therapeutic foodslocally produced therapeutic foods | Dietary supplement | RUTF local_1, RUTF local_2, RUTF local_3, RUTF local_4, RUTF standard |
Primary outcome
short-term acceptability
Time frame: consumption of at least 50% of RUTF provided in a 30 minute period
Passing the appetite test
long-term acceptability
Time frame: Number of children not finishing the 8 week intervention
drop-out during the intervention
weight gain over the 8 week intervention
Time frame: weight gain expressed as weight gain (g)/kg body weight per day over the 8 week intervention
weight gain (in g) over 8 week intervention
5 secondary outcomes
recovery rate
Time frame: from baseline to end of the 8 week intervention
increase in height for age Z scores (HAZ)
Time frame: from baseline to the end of the 8 week intervention
length of stay in the treatment
Time frame: 8 week intervention or shorter
Morbidity during the intervention
Time frame: from baseline to 8 week intervention
Perception
Time frame: based on the interview with the caregiver after the 8 week intervention
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Nov 2022.
- Individual participant dataSharing planned: Undecided. Yes, IP data will be available upon request
Related trials for Severe Acute Malnutrition
Active, not recruiting
Milk Fat Globule Membrane-Enhanced RUTF for Children With Severe Acute Malnutrition
Severe Acute Malnutrition, Cognitive Impairment
Not yet recruiting
The Relapse to Acute Malnutrition Prevention (RAMP) Trial
Acute Malnutrition in Childhood, Acute Malnutrition, Severe
RecruitingPhase 4
Opportunistic Pneumococcal Immunisation Trial in MALnutrition
Severe Acute Malnutrition in Childhood, Pneumococcal Disease
Recruiting
Increasing the Coverage of Severe Acute Malnutrition (SAM) Treatment in Ethiopia
Acute Malnutrition, Severe, Malnutrition, Child
Active, not recruiting
Choline to Improve Malnutrition and Enhance Cognition
Severe Acute Malnutrition, Cognitive Impairment
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Frank Wieringa, MD PhD principal investigator
Institute de Recherche pour le Développement
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Ready to use therapeutic foods in people with Severe Acute Malnutrition, run by Institut de Recherche pour le Developpement at 1 site in Indonesia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Nov 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Indonesia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
short-term acceptability (time frame: consumption of at least 50% of RUTF provided in a 30 minute period). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Nov 2022.